Beta Drugs (NSE:BETA) FFO


NSE:BETA Beta Drugs Ltd NSE:BETA
82 GF Score
Price ₹2,096.60
GF Value ₹1,960.95
Valuation Fairly Valued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs FFO?

FFO (Funds from operations) only applies to REITs.

NSE:BETA
82GF Score
Beta Drugs Ltd NSE:BETA
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,096.60 is trading 6.9% above its estimated GF Value™ of ₹1,960.95. GuruFocus considers Beta Drugs to be Fairly Valued.

Key valuation signals for NSE:BETA:

  • FFO:
  • GF Value™: ₹1,960.95 vs. price of ₹2,096.60 (6.9% above fair value)
  • GF Score™: 82/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
82GF Score

Get the complete analysis for NSE:BETA

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,096.60
Price
₹1,960.95
GF Value